Robert Blum

speaker

321 appearances 1 recordings 1 series first heard Feb 2026 last heard 3 Feb

Robert Blum’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Precision Cardiology With Cytokinetics · 3 Feb 2026 podcast

But to your point, we don't have to reach every cardiologist and certainly not at the same time.

It's incumbent upon us to ensure category growth and broader category penetration.

Yes, and I think that's a good example, but of a market that's more mature in terms of disease education, awareness, adherence, and compliance than is the market we're entering.

So Pfizer did a great job, followed by BridgeBio and Anilum, to be enabling of that business, as we foresee can also be the case for cardiac myosin inhibitors.

And we hope to be the catalyst to be supportive of that happening, hopefully as starts with obstructive HCM.

And if we are fortunate to have a positive phase three study readout in Q2, Acacia HCM is a trial that could open the aperture on non-obstructive HCM and where we believe

Mycorzo could be enabling of patients with NHCM to benefit from this pharmacology as well.

So yeah, I think what you are highlighting in the amniidosis space is a good comp or proxy for what we hope to build here.

And not only in the United States, but also globally.

And similarly, we have the same sorts of expectations and ambitions in advanced heart failure with reduced ejection fraction, as well as advanced heart failure with preserved ejection fraction.

So it's core to our strategy to do just what you're describing.

Yeah, this is not a highly managed category.

And therefore, we don't think it's in anyone's interest to compete on price.

We priced at parity plus a modest premium.

We don't expect to compete on market access.

We believe that the clinical profile of mycorrhizal should be enabling of our aspirations towards best in class, but it won't be based on price or market access.

We think this market opportunity will be defined by classical parameters like safety, efficacy, and patient and physician experience.

Our payer interactions would not suggest that.

It may happen down the road, and we'll be prepared for that if it is, but not at least at this time.

So our pivotal study that led to this first approval, a study called Sequoia HCM, showed superiority of afikamt and now called mycorso as was added to beta blocker therapy versus beta blocker therapy alone.

Showing 101–120 of 321 · page 6 of 17